Skip to content

Ayurveda as Prophylaxis for Suspected COVID-19 Patients

Effect of Ayurveda as Prophylaxis for Suspected Covid-19 Patients: Randomised Controlled Trial

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04395976
Enrollment
0
Registered
2020-05-20
Start date
2020-05-10
Completion date
2020-09-01
Last updated
2021-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19

Keywords

Ayurveda

Brief summary

Despite worldwide efforts to contain, manage and treat Covid-19, the pandemic is continuing to spread. This calls for an urgent clinically-proven prophylaxis and therapeutic strategy. Recent developments on the use of traditional medicines in Covid-19 management has drawn enough attention to start several research studies. Based on the Indian Traditional Medicine, Ayurveda's community initiatives, preliminary studies, and our experiential knowledge on Covid-19 settings, we propose present study to prevent the development of COVID-19 symptoms in people who live or have come contact with an individual diagnosed with COVID-19.

Interventions

The Ayurveda intervention is multimodal and following the principles of Ayurveda as a whole medical system, each participants will be treated with individualised care. From the range of proven Ayurvedic Herbs, combination will be decided based on individual participants, his symptoms and his personality.

Sponsors

All Party Parliamentary Group - Indian Traditional Sciences
CollaboratorUNKNOWN
University of Warwick
CollaboratorOTHER
British Ayurvedic Medical Council
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Person who has come into contact with confirmed COVID-19, * Willing to take study drug as directed

Exclusion criteria

* Confirmed current COVID-19 * Inability to take medications orally * Inability to provide written consent

Design outcomes

Primary

MeasureTime frameDescription
Clinical confirmation of Covid-19From date of enrolment to 14 daysNumber of participants with symptomatic, lab-confirmed COVID-19

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026